HOME >> MEDICINE >> NEWS
Second patient with multiple sclerosis undergoes groundbreaking surgery at Yale

New Haven, Conn. A 29-year-old man with multiple sclerosis is the second patient to undergo transplantation surgery at Yale in an effort to repair myelin, the protective brain and spinal cord sheath that is destroyed by the disease, Yale researchers have reported.

The surgery took place in two stages March 6-7 and the patient was discharged from Yale-New Haven Hospital March 10. The young man is the second of five patients who are scheduled to participate in the groundbreaking clinical trial.

"The patient is doing fine," said Timothy Vollmer, M.D., associate professor of neurology at Yale School of Medicine. "He has a high level of disability because of the location of the lesions in the brain, but he is otherwise healthy."

There are an estimated 1.4 million persons worldwide with multiple sclerosis. The young man in the trial suffers from a relapsing form of multiple sclerosis, which Vollmer said is the most common form of multiple sclerosis. It affects three times as many women as men.

Vollmer said he and his team hope to perform the procedure on a third patient next month.

The purpose of the Phase One trial is to determine whether cells found in the bodys peripheral nerves, in this case, the ankle, can safely repair the damaged cells in the brain and spinal cord that result in neurologic disability in patients with multiple sclerosis and other disorders of myelin.

In multiple sclerosis, the immune system attacks the brains nerve fibers and strips away the protective myelin sheath around nerve fibers in the spinal cord and brain. The resulting lesions make it difficult for the nerves to transmit messages.

In the first procedure on March 6, the surgical team harvested Schwann cells from the patients ankle. Animal studies show that Schwann cells can replace the cells that generate the myelin. The second day, the cells were injected into the left posterior aspect of the patients brain, which has lesi
'"/>

Contact: Jscqueline Weaver
jacqueline.weaver@yale.edu
203-432-8555
Yale University
14-Mar-2002


Page: 1 2

Related medicine news :

1. Secondhand smoke linked to cervical cancer
2. Second NIAID SARS vaccine candidate helps mice fend off SARS
3. Secondhand smoke impairs lung function in women
4. Second stage of HIV vaccine trial begins in London and Oxford, UK
5. Cholesterol Carriers Better Predictors Than Cholesterol For Second Heart Attack
6. Second Annual AIDS Vaccine Day Honors Volunteers Nationwide
7. Patients Treated Successfully For Hodgkins Disease Are At 9 Times The Risk For Developing Second Cancer
8. Cedars-Sinai Medical Centers Prenatal Program Pushes the Frontiers of Diagnosis From the Second Trimester Into the First
9. AAPS Sponsors Second Frontier Symposium
10. Drug Combination Including New "Super Aspirin" Drug Cuts Risk Of Death Or Second Heart Attack
11. Drugs Effect On Chromosomes May Explain Second Cancers

Post Your Comments:
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... memories? How did it make you feel? According to ... experience, such as how sad you were or how ... when you can,t stop thinking about it. , ... context of the memories, rather than how you felt, ... the negative effects of these memories, a new study ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
Cached News: